Table 2.
Intra- and postoperative course and medical complications
| ADPKD group (n = 193) |
Matched control group (n = 193) |
p value | |
|---|---|---|---|
| Initial Immunosuppression | |||
| CNI/MPA/steroids (in %) | 191 (99.0%) | 189 (97.9%) | 0.6850 |
| IL2-RA (in %) | 114 (59.1%) | 104 (53.9%) | 0.3555 |
| ATG (in %) | 12 (6.2%) | 11 (5.7%) | 1.0000 |
| Rituximab/immunoadsorption (in %) | 22 (11.4%) | 23 (11.9%) | 1.0000 |
| Intra- and perioperative course | |||
| Operative time (in min.) | 169.0 (95% CI 159.8–175.6) | 139.0 (95% CI 131.4–145.0) | < 0.0001 |
| Anastomosis time (in min.) | 26.0 (95% CI 25.0–29.0) | 29.0 (95% CI 27.0–30.0) | 0.0186 |
| Weight of polycystic kidney (in g) | 1879.8 ± 162.9 | ||
| Malignant specimen (in %) | 2 (1.0%) | ||
| Delayed graft function (in %) | 5 (2.6%) | 4 (2.1%) | 1.0000 |
| Hospital stay (in d) | 19.0 (95% CI 18.0–20.0) | 18.0 (95% CI 17.0–19.0) | 0.1292 |
| Intensive care unit stay (in d) | 0.0 (95% CI 0.0–0.0) | 0.0 (95% CI 0.0–0.0) | 0.9512 |
| Immunological and infectious course | |||
| Renal biopsies within 30 days (in %) | 50 (25.9%) | 45 (23.3%) | 0.6366 |
| Biopsy proven acute rejections ≤ 30days (in %) | 16 (8.3%) | 23 (11.9%) | 0.3109 |
| Inpatient CMV infections > 1000 copies (in %) | 5 (2.6%) | 12 (6.2%) | 0.1346 |
| Inpatient UTI (in %) | 78 (40.4%) | 56 (29.0%) | 0.0246 |
| Postoperative pneumonia (in %) | 5 (2.6%) | 9 (4.7%) | 0.4152 |
Data are n (%) or median ± 95% CI. p values are estimated with Mann-Whitney U test for calculated data, and 2-tailed Fisher’s exact test for categorical data. Weight of polycystic kidney is expressed in mean ± SD